Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Vaccine

• Publication date

  2011-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2011.04.038PMID 21539882PMCID PMC3114163
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.

  2011cited by this paper
• Transmission of Childhood Tuberculosis: Risk Factors Associated With an Unidentified Index Case and Outbreak Evolution in Barcelona (1987–2007)

  2010cited by this paper
• Antibodies to serotype 9V exhibit novel serogroup cross-reactivity following infant pneumococcal immunization.

  2010cited by this paper
• INVASIVE PNEUMOCOCCAL DISEASE IN FIJI CLINICAL SYNDROMES , EPIDEMIOLOGY , AND THE POTENTIAL IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINE

  2010cited by this paper
• Results from an inter-laboratory comparison of pneumococcal serotype-specific IgG measurement and critical parameters that affect assay performance.

  2010cited by this paper
• Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.

  2010cited by this paper
• Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.

  2010cited by this paper
• Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine.

  2009cited by this paper
• Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates.

  2009cited by this paper
• First report of putative Streptococcus pneumoniae serotype 6D among nasopharyngeal isolates from Fijian children.

  2009cited by this paper
• 6th International Symposium on Pneumococci and Pneumococcal Diseases

  2008cited by this paper
• Pneumococcal conjugate vaccine for childhood immunization--WHO position paper.

  2007cited by this paper
• Discovery of a New Capsular Serotype (6C) within Serogroup 6 of Streptococcus pneumoniae

  2007cited by this paper
• Immunogenicity and Boosting After a Reduced Number of Doses of a Pneumococcal Conjugate Vaccine in Infants and Toddlers

  2006influential reference
• Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine.

  2005cited by this paper
• Kinetics and Avidity of Antibodies Evoked by Heptavalent Pneumococcal Conjugate Vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial

  2005cited by this paper
• Correlates of immunity for pneumococcal conjugate vaccines.

  2003cited by this paper
• Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

  2003cited by this paper
• Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant.

  2001influential reference
• Avidity as a Determinant of the Protective Efficacy of Human Antibodies to Pneumococcal Capsular Polysaccharides

  1999cited by this paper
• Contribution of serotype‐specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae

  1999cited by this paper
• Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood.

  1999influential reference
• Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines.

  1998cited by this paper
• Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization.

  1998cited by this paper
• Laboratory Correlates of Protection against Haemophilus influenzae Type b Disease

  1995cited by this paper
• Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugates.

  1995cited by this paper
• Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.

  1992cited by this paper
• Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants.

  1992cited by this paper
• Weekly Epidemiological Record Relevé Épidémiologique Hebdomadaire World Health Organization Geneva Organisation Mondiale De La Santé Genève Summary and Conclusions

  year unknowncited by this paper

• Serotype 3 Antibody Response and Antibody Functionality Compared to Serotype 19A Following 13-Valent Pneumococcal Conjugate Immunization in Children

  2023cites this paper
• Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study.

  2023cites this paper
• Quality of antibody responses by adults and young children to 13-valent pneumococcal conjugate vaccination and Streptococcus pneumoniae colonisation

  2022cites this paper
• Vaccination of immune-deficient patients

  2020cites this paper
• The Immunology of Sepsis – Understanding Host Susceptibility, Pathogenesis of Disease, and Avenues for Future Treatment

  2020influential citation
• Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children

  2019cites this paper
• Protection Against Invasive Infections in Children Caused by Encapsulated Bacteria

  2018cites this paper
• Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea

  2017cites this paper
• Comparison of Anti-pneumococcal Antibodies in Cord Blood From Australian Indigenous and Gambian Neonates and the Implications for Otitis Media

  2014cites this paper
• Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine

  2014cites this paper
• Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule.

  2014cites this paper
• Vaccination for the control of childhood bacterial pneumonia — Haemophilus influenzae type b and pneumococcal vaccines

  2013cites this paper
• Healthcare associated infections in children-where are we now ?

  2012cites this paper
• Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses.

  2012cites this paper
• Use of pneumococcal polysaccharide vaccine in children: what is the evidence?

  2012cites this paper
• Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.

  2011cites this paper